Introduction
============

SNPs are useful in mapping disease susceptibility genes. However, the SNPs identified from typical genetic mapping studies often are not the causal SNPs but may tag the true causal mutation if they are in linkage disequilibrium with each other (Ardlie et al., [@B2]; Gabriel et al., [@B8]; Ke et al., [@B9]). To increase heterozygosity, genetic information, and statistical power, haplotypes are usually reconstructed from observed genotypes to identify the individuals carrying the risk haplotypes. Haplotypes are also valuable for exploring cis-effects of specific combinations of intragenic polymorphisms, such as those variations located in gene promoters, or polymorphisms in closely linked genes where there may be interaction that affects gene expression (Levenstien et al., [@B11]; Fan et al., [@B7]).

Statistical and computational methods can provide highly accurate estimates of haplotypes reconstructed from conventional genotype data in most situations, but even the best method can have a large error rate of more than 35% for datasets where parental genotypes are unknown (Stephens and Donnelly, [@B19]; Marchini et al., [@B15]; Browning, [@B4]; Liu et al., [@B13]). Several experimental methods for haplotype and genetic phase determination have been reported, including cloning (Burgtorf et al., [@B5]; Kitzman et al., [@B10]), hybridization (Yan et al., [@B21]; Douglas et al., [@B6]; Boldt and Petzl-Erler, [@B3]), polony technology (Mitra et al., [@B17]), MALDI-TOF mass spectrometry (Tost et al., [@B20]), sequencing (Levy et al., [@B12]), and chromosome micro-dissection (Ma et al., [@B14]). However, these methods are labor-intensive and/or require specialized and expensive equipment. PCR-based methods, such as allele-specific PCR and isolation of single DNA molecules have been used in the past to determine haplotypes and genetic phase (Ruano et al., [@B18]; Michalatos-Beloin et al., [@B16]; Zhang et al., [@B22]), but experimental optimization is needed and/or is labor-intensive. All of the above methods may not be applicable in settings where cost is a premium and specialized equipment is not available or personnel have little or no training in labor-intensive methodologies.

We present here a simple application of the popular PCR--RFLP based strategy to determine the genetic phase at two adjacent SNPs in compound heterozygous individuals. Specifically, we looked at rs909253 (A \> G) at position +252 of the lymphotoxin alpha (*LTA*) gene and about 3 kb downstream, rs1800629 (G \> A), at position −308 of the tumor necrosis factor (*TNF*) alpha gene in the major histocompatibility complex. Using this method, we determined the phase of these two SNPs in nine individuals shown in a previous study to be heterozygous both at the *LTA* +252 and the *TNF* −308 positions (Aissani et al., [@B1]).

Materials and Methods
=====================

DNA was extracted from peripheral blood mononuclear cells (Qiagen, Valencia, CA, USA) obtained from nine subjects who were double heterozygotes for the *LTA* +252 and *TNF* −308 SNPs (Aissani et al., [@B1]). Human subject approval was given by the Institutional Review Board at UAB and informed consent was obtained from all subjects. DNA quantitation was determined by a fluorometric method using the Qubit™ fluorometer (Invitrogen, Carlsbad, CA, USA). For the first PCR, 50 ng of DNA from each subject were used to amplify the 3.4-kb fragment separating the *LTA* and *TNF* SNPs. Due to the large size of the fragment to be amplified and its high GC content (75%), we used the Qiagen LongRange PCR kit. All primers were designed using Primer 3 (<http://frodo.wi.mit.edu/primer3/>). A final concentration of 0.4 μM of primers L--T forward (5′-GCTTCGTGCTTTGGACTACC-3′) and reverse (5′-GTCCTTTCCAGGGGAGAGAG-3′) were added to a 25-μl reaction containing 2.5 mM Mg^++^, 500 μM of each dNTP, 1× Q-solution, and two units of enzyme. DNA amplification was performed at an initial denaturation at 95°C for 3 min followed by 35 cycles of denaturation at 95°C/30 s, annealing at 62°C/30 s, and extension at 68°C for 3 min. After product specificity was tested and confirmed by agarose gel electrophoresis, the products were purified using the Qiagen PCR purification kit. Approximately 5 μl of 25 μl purified product were digested with two and one-half units of *Nco*I restriction endonuclease enzyme (NEB, Ipswich, MA, USA) in a total reaction of 25 μl for 1 h at 37°C. The digested and undigested samples were run in adjacent lanes along with a 1-kb size standard (Fermentas, Glen Burnie, MD, USA) on a 1.2% agarose gel. The samples were run first for 16 h at 20 V constant overnight and then 40 V for 7 h in order to obtain sufficient separation of the fragments for removal from the gel. The gel was stained with ethidium bromide for 30 min, followed by destaining in 1× TBE for 10 min. Under low UV light, the shorter 3.2 kb digested *Nco*I fragment containing the G allele at *LTA* +252 was identified and sliced from the gel.

The DNA fragment was eluted from the gel slice using the QIAquick Gel Extraction Kit. For the second PCR, *TNF* forward (5′-GCCCCTCCCAGTTCTAGTTC-3′) and reverse (5′-TTGGAAAGTTGGGGACACAC-3′) primers were designed to flank the *TNF* −308 site. We generated a 248-bp PCR fragment from 1 μl of gel purified product in a 20-μl reaction containing 0.5 μM each of primers and standard PCR reagents (200 μM dNTPs, 1.5 mM Mg^++^, and one unit of Amplitaq; Applied Biosystems, Foster City, CA, USA). After an initial denaturation at 95°C for 3 min, 35 cycles of denaturation at 95°C/30 s, annealing at 56°C/30 s, and extension at 72°C/30 s were performed, followed by a final extension of 72°C for 5 min. The PCR product was purified through silica columns (Qiagen, Valencia, CA, USA) to remove dNTPs and non-incorporated primers. To identify the allele at the *TNF* −308 site, the nucleotide sequence of the purified 248 bp fragment was determined by Big Dye terminator cycle sequencing on a 3730 Genomic Analyzer (Applied Biosystems, Forrest City, CA, USA) using the *TNF* reverse primer.

Results
=======

Figure [1](#F1){ref-type="fig"} shows the locations of the *LTA* +252 and *TNF* −308 SNPs in the initial 3.4 kb PCR product and in the resulting 3.2 kb *Nco*I digested fragment when the "G" allele is present at the *LTA* +252 site. Since each of the nine samples was heterozygous for the *LTA* +252 SNP (A \> G), digestion of the PCR product with *Nco*I generated DNA fragments of 3.4 and of 3.2 kb of length carrying the "A" and the "G" alleles, respectively (Figure [2](#F2){ref-type="fig"}). Because allele "G" of *LTA* +252 can occur with either "A" or "G" allele of *TNF* −308, genetic phase was determined by sequencing the 3′ end of the 3.2-kb *Nco*I fragment that encompasses the *TNF* −308 site. Figure [3](#F3){ref-type="fig"} shows the DNA sequences surrounding the *TNF* −308 site in the nine tested samples. As can be seen, all nine samples carry the *TNF* −308 "A" allele (displayed as the "T" allele on the reverse strand). Therefore, all nine subjects who had the "G" allele at the *LTA* +252 site possess the "A" allele at the *TNF* −308 site. Since all nine individuals are known compound heterozygotes (Aissani et al., [@B1]), the phase on the other chromosome must be *LTA* +252 (A) -- *TNF* −308 (G).

![**Location of *LTA* +252 and *TNF* −308 SNPs in PCR product and *Nco*I fragment**.](fgene-02-00108-g001){#F1}

![**Gel separation of digested and undigested *Nco*I fragments**. Lane 1: 1 kb size std.; Lane 2: *Nco*I digest of PCR from subject 1; Lane 3: first PCR product from subject 1.](fgene-02-00108-g002){#F2}

![**Sample sequences of *TNF* −308 SNP on *Nco*I digested fragment (3**′ **strand)**. "T" nucleotide on the 3′ strand represents the *TNF* −308 "A" allele on 5′ strand.](fgene-02-00108-g003){#F3}

Discussion
==========

For population studies where often hundreds or thousands of individuals are sampled, phase determination can usually be statistically inferred, i.e., probabilistically. Family data can also assist in determining phase. However, if only a few subjects are genotyped, determining phase usually must rely on laborious methods such as purification of single molecules to isolate the alleles. Allele-specific PCR is relatively simple but is limited by the demand of allele-specific oligos which may not always be compatible with efficient amplification. The PCR--RFLP technique we present here is a simple, cost--effective way to determine phase when compound heterozygotes are present, especially in studies of small sample size or when family data are not available. This method does not require expensive equipment and can be performed with the basic tools found in most laboratories with only moderate technical experience. There are a couple of factors that can affect or even restrict the use of this technique. If one of the SNPs is not a restriction site, allele-specific PCR could be utilized as an alternative. However, our method is more flexible than allele-specific PCR as any heterozygous site upstream of the SNP sites of interest could be used to generate fragments with different electrophoretic mobilities, although sequencing across both SNPs on the shorter fragment would be necessary. Here, there was no need to sequence through the *LTA* +252 site because the allele was determined by RFLP. Size is an obvious limitation of the technique we present here since a template of ∼40 kb approaches the upper limit for successful amplification. Finally, some initial optimization of PCR and electrophoretic conditions, such as the presence of difficult sequences (e.g., GC content) and similarly sized cut and uncut fragments, may be necessary.

We present here a simple, cost--effective method for determining genetic phase between SNPs in compound heterozygotes. We were able to use this PCR--RFLP procedure to determine phase for two SNPs that are 3 kb apart in nine such individuals. Specifically, using this procedure, we show that allele A of *TNF* −308 is in complete disequilibrium with allele G of *LTA* +252. This procedure would be very helpful for diseases or conditions where the clinical manifestation and/or outcome are associated with haplotypes. Except for sequencing, which can be outsourced to relatively inexpensive sequencing services, this procedure can be performed in most labs with only moderate technical experience and with no expensive equipment or high up-front cost. This technique could eventually be applied in clinical settings where disease susceptibility or variability in expression is an urgent need. Although there are certain situations that can limit the practical use of this approach, the simple design, and relatively inexpensive cost makes it a viable alternative to current methods.
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